BMB is happy to announce the completion of its one year safety and performance study of Bonevolent™- AdhFix on rodant. The study was conducted in collaboration with KTH Royal Institute of Technology, South Stockholm General Hospital and RISE Research Institutes of Sweden.
"The results were much anticipated and AdhFix performed over our expectation. This is the final milestone prior to any clinical verification and well aligned with our activities."
- Michael Malkoch, CEO of BMB